Key result
Early screening and cardioprotectants like dexrazoxane mitigate anthracycline-induced cardiotoxicity driven by oxidative injury.
Why the study?
Anthracycline use in cancer treatment is limited by dose-related cardiotoxicity, necessitating evaluation of screening and cardioprotective strategies.
This review highlights strategies to mitigate anthracycline-induced cardiotoxicity, including early screening and the use of cardioprotective agents.
Answers are grounded in this paper and cite their sources.
Screening may curb chronic anthracycline cardiomyopathy; leaves open optimal modalities and timing in modern regimens.
Anthracyclines are important chemotherapeutic agents that are used for the treatment of various malignancies in both adults and children, but their usefulness has been limited by cardiotoxicity that is usually dose related. Oxidative injury appears to be the cause of myocardial dysfunction when using these drugs. Screening for early myocardial injury with troponin testing, echocardiography, and radionuclide examinations has reduced the incidence of chronic cardiac dysfunction. Various anthracycline analogues have been developed that have less cardiotoxicity. Dexrazoxane, an iron chelator, and the radioprotective agent amifostine protect against cardiac injury, thus allowing the use of higher doses of anthracyclines. Other strategies that have been evaluated are dietary glutamine supplementation and the use of the antioxidant probucol.
No takes yet. Share an insight, caveat, or question.
Nelson et al. (2001) conducted a review in Cancer. Anthracyclines was evaluated. Anthracycline-induced cardiotoxicity, primarily caused by oxidative injury, can be mitigated through early screening and the use of protective agents like dexrazoxane or less toxic analogues.
Synapse has enriched 10 related papers. Consider them for comparative context: